You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. TFEB Activator for Alzheimer's Disease Therapy

    SBC: BRILLIANT BIOSCIENCES INC.            Topic: NIA

    One in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Small molecule Inhibitors of steroid receptor coactivator to treat breast cancer

    SBC: Coactigon, Inc.            Topic: 102

    ABSTRACTSteroid Receptor CoactivatorSRCis a key breast cancer oncogene that is frequently overexpressed or amplified in estrogen receptorERand human epidermal growth factor receptorHERpositive breast cancersElevated expression of SRCalso has been associated with resistance to tamoxifen therapy and with poor disease outcome in HERpositive breast cancersNumerous studies have shown that experimental ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Humanized EMAP II mAb as a Novel Therapy for Viral-Associated Lung Injury

    SBC: Allinaire Therapeutics, LLC            Topic: NHLBI

    Summary Abstract The ultimate goal of this project is the validation of a humanized endothelial monocyteactivating protein IIEMAP IIneutralizing monoclonal antibodymAbfor progression to clinical evaluation as a novel treatment for patients with influenza associated lung injuryInfection with influenza virusIAVremains a major world wide health threat to high risk populations including the young and ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. 3D Holographic Guidance, Navigation, and Control (3D GN&C) for Endovascular Aortic Repair (EVAR)

    SBC: CENTERLINE BIOMEDICAL INC            Topic: NHLBI

    Project Summary This project will develop newD visualization to improve stent graft deployment during minimally invasive endovascular aortic repairEVARby overcoming limitations ofD x ray fluoroscopyfluoroD holographic guidancenavigation and controlD GNandamp Cwill be provided to decrease fluoro radiation dose burden to patients and OR staff during treatment of aortic aneurysmsparticularly when dep ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Enzymatic attachment of proteins to fluorescent nanodiamond surfaces.

    SBC: COLUMBUS NANOWORKS, INC.            Topic: 400

    Fluorescent nanodiamonds are biocompatibleinfinitely photostableand fluoresce in a variety of wavelengthsincluding the near infraredNIRregionThese characteristics suggest transformative applications in areas ranging from pure biological research to biomedical imagingwhere protein conjugated nanodiamonds could be targeted to specific tissues in living patients or even structures within individual c ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's Disease

    SBC: Amprion, Inc.            Topic: NIA

    ABSTRACT This proposal is for a phase I II fast track project for the STTR program with the main goal to develop a test for high sensitive detection of tau oligomers in biological fluidswhich could be used for the biochemical diagnosis of Alzheimerandapos s diseaseADand related tauopathiesAD is the most common dementia in the elderly population and one of the leading causes of death in the develop ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Enhancing Clinical Therapy for wet Age-related Macular Degeneration (wetAMD)

    SBC: NANOHYBRIDS INC            Topic: N

    ABSTRACTThe wet form of age related macular degenerationAMDaccounts forof all AMD related blindness and affectsmillion people withnew cases each year in the USMinimally invasive and selective drug delivery to the eye still remains an open challengethe current standard of care involves delivery of antivascular endothelial growth factoranti VEGFdrugs via intraocular injectionFor patients refractory ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a novel platform for rapid identification of drug targets and anti-targets

    SBC: Truvitech, LLC            Topic: NCATS

    PROJECT SUMMARY Drugs act by altering the activities of particular componentstargetswithin a cell or organismThusdrug discovery campaigns begin by identifying a targetfollowed by screening this target with compounds to identify leads that can be developed into a drugUnfortunatelyidentifying effective drug targets for a given diseaselet alone for individual patientse gin highly heterogeneous cancer ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical Development of 2nd Generation HIV Maturation Inhibitors

    SBC: DFH Pharma, Inc            Topic: 400

    Project SummaryDespite advances in the development of HIV drugs there remains a need for new therapiesToxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antiviralsMaturation inhibitorsMIsrepresent one such class of HIV therapiesHIV maturation inhibitors block virus replication by disrupting the con ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government